• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用动态光学相干断层扫描技术鉴定光化性角化病的治疗抵抗和治疗反应的血管特征。

Vascular Characteristics of Treatment-resistant and -responsive Actinic Keratosis Identified with Dynamic Optical Coherence Tomography.

机构信息

Department of Dermatology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark.

Department of Dermatology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.

出版信息

Acta Derm Venereol. 2024 Nov 25;104:adv42190. doi: 10.2340/actadv.v104.42190.

DOI:10.2340/actadv.v104.42190
PMID:39585185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609724/
Abstract

Treatment-resistant actinic keratosis (AK) is of concern in clinical practice, often requiring retreatment. Microvascular assessments might help differentiate treatment-resistant from treatment-responsive AKs, enabling targeted treatment. Using dynamic optical coherence tomography, AK vascularization was investigated following daylight photodynamic therapy, comparing treatment-resistant with cleared AKs. AKs on face/scalp were graded according to the Olsen Classification Scheme and scanned with dynamic optical coherence tomography pre-treatment, and 3- and 12-months post-treatment. Employing dynamic optical coherence tomography, total vessel length, mean vessel length, mean vessel diameter, vessel area density, and branchpoint density were quantified. Thirty-eight patients with 62 AKs were enrolled, including 37 AK I, 18 AK II, and 7 AK III. Treatment-resistant AKs displayed a trend toward intensified vascularization compared with cleared AK at baseline (AKs I, II), suggested by higher total vessel length (median 144.0, IQR 104.3-186.6) and vessel area density (median 27.7, IQR 18.4-34.2) than in cleared AK (median 120.9, IQR 86.9-143.0 and median 22.9, IQR 17.3-26.8). Additionally, vascularization in treatment-resistant AK I-II appeared disorganized, with trends toward shorter mean vessel length (median 151.0, IQR 138.5-167.5) and increased branchpoint density (median 3.2, IQR 2.3-3.8) compared with cleared AK (median 160.0, IQR 152.0-169.3 and median 2.6, IQR 2.2-3.0). These findings suggest that dynamic optical coherence tomography holds potential to identify treatment-resistant AKs.

摘要

治疗抵抗性光化性角化病(AK)在临床实践中受到关注,通常需要再次治疗。微血管评估可能有助于区分治疗抵抗性和治疗反应性 AK,从而实现靶向治疗。本研究采用动态光学相干断层扫描(OCT)技术,比较治疗抵抗性和清除性 AK 患者,评估日光光动力疗法(PDT)后 AK 的血管生成情况。根据 Olsen 分类方案对面部/头皮 AK 进行分级,并在治疗前、治疗后 3 个月和 12 个月进行动态 OCT 扫描。采用动态 OCT 技术,定量分析总血管长度、平均血管长度、平均血管直径、血管面积密度和分叉密度。共纳入 38 例 62 处 AK 患者,包括 37 处 AK I 级、18 处 AK II 级和 7 处 AK III 级。与清除性 AK 相比,治疗抵抗性 AK 基线时(AK I 级和 AK II 级)的血管化程度呈加重趋势,总血管长度(中位数 144.0,IQR 104.3-186.6)和血管面积密度(中位数 27.7,IQR 18.4-34.2)均高于清除性 AK(中位数 120.9,IQR 86.9-143.0 和中位数 22.9,IQR 17.3-26.8)。此外,治疗抵抗性 AK I-II 的血管化程度紊乱,平均血管长度(中位数 151.0,IQR 138.5-167.5)和分叉密度(中位数 3.2,IQR 2.3-3.8)较清除性 AK 缩短和增加(中位数 160.0,IQR 152.0-169.3 和中位数 2.6,IQR 2.2-3.0)。这些发现提示动态 OCT 可能有助于识别治疗抵抗性 AK。

相似文献

1
Vascular Characteristics of Treatment-resistant and -responsive Actinic Keratosis Identified with Dynamic Optical Coherence Tomography.利用动态光学相干断层扫描技术鉴定光化性角化病的治疗抵抗和治疗反应的血管特征。
Acta Derm Venereol. 2024 Nov 25;104:adv42190. doi: 10.2340/actadv.v104.42190.
2
Vascular feature identification in actinic keratosis grades I-III using dynamic optical coherence tomography with automated, quantitative analysis.使用具有自动定量分析功能的动态光学相干断层扫描技术对 I-III 级光化性角化病的血管特征进行识别。
Arch Dermatol Res. 2024 Jun 15;316(7):391. doi: 10.1007/s00403-024-03022-z.
3
Dynamic optical coherence tomography unveils subclinical, vascular differences across actinic keratosis grades I-III.动态光学相干断层扫描揭示了 I-III 级光化性角化病各等级的亚临床血管差异。
Exp Dermatol. 2024 Aug;33(8):e15153. doi: 10.1111/exd.15153.
4
Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.使用氨基乙酰丙酸对面部和头皮非角化过度性光化性角化病患者进行光动力疗法:一项为期12个月随访的IV期多中心临床试验。
Br J Dermatol. 2006 Dec;155(6):1262-9. doi: 10.1111/j.1365-2133.2006.07520.x.
5
Artificial White Light vs Daylight Photodynamic Therapy for Actinic Keratoses: A Randomized Clinical Trial.人工白光与日光光动力疗法治疗光化性角化病的随机临床试验。
JAMA Dermatol. 2016 Jun 1;152(6):638-44. doi: 10.1001/jamadermatol.2015.5436.
6
Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight.德国真实环境中使用甲基氨基乙酰丙酸的人工日光光动力疗法:非干预性研究ArtLight的结果
Br J Dermatol. 2025 Feb 18;192(3):510-519. doi: 10.1093/bjd/ljae437.
7
Single versus two-treatment schedule of methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient randomized trial.单剂量与双剂量甲氨基酮戊酸日光光动力疗法治疗面部和头皮光化性角化病的随机患者内试验。
Photodiagnosis Photodyn Ther. 2019 Sep;27:100-104. doi: 10.1016/j.pdpdt.2019.05.031. Epub 2019 May 26.
8
Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy.传统与日光甲基氨基乙酰丙酸光动力疗法治疗面部和头皮光化性角化病:意大利一项患者内前瞻性比较研究
J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1926-32. doi: 10.1111/jdv.13076. Epub 2015 Mar 23.
9
Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study.日光介导的光动力疗法治疗面部和头皮中至厚的光化性角化病:一项随机多中心研究。
Br J Dermatol. 2012 Jun;166(6):1327-32. doi: 10.1111/j.1365-2133.2012.10833.x.
10
A randomized split-scalp study comparing calcipotriol-assisted methyl aminolaevulinate photodynamic therapy (MAL-PDT) with conventional MAL-PDT for the treatment of actinic keratosis.一项比较卡泊三醇辅助氨甲环酸光动力疗法(MAL-PDT)与常规 MAL-PDT 治疗光化性角化病的随机头皮分裂研究。
Br J Dermatol. 2018 Oct;179(4):829-835. doi: 10.1111/bjd.16473. Epub 2018 May 15.

本文引用的文献

1
Dynamic optical coherence tomography unveils subclinical, vascular differences across actinic keratosis grades I-III.动态光学相干断层扫描揭示了 I-III 级光化性角化病各等级的亚临床血管差异。
Exp Dermatol. 2024 Aug;33(8):e15153. doi: 10.1111/exd.15153.
2
The "Personalising Actinic Keratosis Treatment for Immunocompromised Patients" (IM-PAKT) Project: An Expert Panel Opinion.“免疫功能低下患者光化性角化病的个性化治疗”(IM-PAKT)项目:专家小组意见
Dermatol Ther (Heidelb). 2024 Jul;14(7):1739-1753. doi: 10.1007/s13555-024-01215-y. Epub 2024 Jun 21.
3
Vascular feature identification in actinic keratosis grades I-III using dynamic optical coherence tomography with automated, quantitative analysis.
使用具有自动定量分析功能的动态光学相干断层扫描技术对 I-III 级光化性角化病的血管特征进行识别。
Arch Dermatol Res. 2024 Jun 15;316(7):391. doi: 10.1007/s00403-024-03022-z.
4
Pre-treatment with topical 5-fluorouracil increases the efficacy of daylight photodynamic therapy for actinic keratoses - A randomized controlled trial.外用5-氟尿嘧啶预处理可提高日光光动力疗法治疗光化性角化病的疗效——一项随机对照试验。
Photodiagnosis Photodyn Ther. 2024 Apr;46:104069. doi: 10.1016/j.pdpdt.2024.104069. Epub 2024 Mar 28.
5
Towards standardising retinal OCT angiography image analysis with open-source toolbox OCTAVA.用开源工具 OCTAVA 实现视网膜 OCT 血管造影图像分析标准化。
Sci Rep. 2024 Mar 12;14(1):5979. doi: 10.1038/s41598-024-53501-6.
6
European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes).欧洲基于共识的跨学科指南:光化性角化病、上皮紫外线诱导发育不良和皮肤癌前病变的诊断、治疗和预防,代表了欧洲皮肤病肿瘤学会、欧洲皮肤病学会、欧洲皮肤性病学会和医学专家联盟(Union Européenne des Médecins Spécialistes)。
J Eur Acad Dermatol Venereol. 2024 Jun;38(6):1024-1047. doi: 10.1111/jdv.19897. Epub 2024 Mar 7.
7
Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review.光化性角化病的区域癌变疗法治疗:更新综述。
Am J Clin Dermatol. 2024 May;25(3):391-405. doi: 10.1007/s40257-023-00839-8. Epub 2024 Feb 13.
8
Digitally Enhanced Methods for the Diagnosis and Monitoring of Treatment Responses in Actinic Keratoses: A New Avenue in Personalized Skin Care.光化性角化病诊断及治疗反应监测的数字增强方法:个性化皮肤护理的新途径
Cancers (Basel). 2024 Jan 23;16(3):484. doi: 10.3390/cancers16030484.
9
Reflectance Confocal Microscopy and Dermoscopy of Facial Pigmented and Non-Pigmented Actinic Keratosis Features before and after Photodynamic Therapy Treatment.光动力治疗前后面部色素性和非色素性光化性角化病特征的反射式共聚焦显微镜检查和皮肤镜检查
Cancers (Basel). 2023 Nov 27;15(23):5598. doi: 10.3390/cancers15235598.
10
Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis.普通人群中光化性角化病的全球流行病学:一项系统评价和荟萃分析。
Br J Dermatol. 2024 Mar 15;190(4):465-476. doi: 10.1093/bjd/ljad371.